弥漫性大 B 细胞淋巴瘤临床试验中替代终点的探索：侵袭性淋巴瘤项目的替代终点。
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.
机构信息
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
出版信息
Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10.
Abstract
This commentary describes the progress of the SEAL [Surrogate Endpoints for Aggressive Lymphoma] research group and invites collaboration in sharing data to continue building a large database of individual patient data from multiple clinical trials in DLBCL.
摘要
本述评介绍了 SEAL [侵袭性淋巴瘤替代终点研究小组] 的研究进展，并邀请合作方共享数据，以继续建立一个来自多个弥漫性大 B 细胞淋巴瘤临床试验的大型个体患者数据数据库。
相似文献
1
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.弥漫性大 B 细胞淋巴瘤临床试验中替代终点的探索：侵袭性淋巴瘤项目的替代终点。
Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10.
2
Surrogate end points for overall survival in breast cancer trials: A review.乳腺癌试验中总生存期的替代终点：综述
Breast. 2016 Oct;29:44-8. doi: 10.1016/j.breast.2016.06.005. Epub 2016 Jul 9.
3
An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.KTE-C19用于难治性侵袭性非霍奇金淋巴瘤的ZUMA-1研究的中期分析。
Clin Adv Hematol Oncol. 2017 Feb;15(2):117-120.
4
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?弥漫性大 B 细胞淋巴瘤临床试验的终点：是否需要更多的对话？
Future Oncol. 2024;20(22):1601-1615. doi: 10.1080/14796694.2024.2357537. Epub 2024 Jun 18.
5
Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.探索因果推断与荟萃分析范式在替代终点评估中的关系。
Stat Med. 2016 Apr 15;35(8):1281-98. doi: 10.1002/sim.6807. Epub 2015 Nov 26.
6
Advances in the management of primary mediastinal large B-cell lymphoma.原发性纵隔大B细胞淋巴瘤的管理进展
Clin Adv Hematol Oncol. 2018 Jan;16(1):33-34.
7
Surrogate endpoints for overall survival in lung cancer trials: a review.肺癌试验中总生存期的替代终点：综述
Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12.
8
Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials.复发性弥漫性大B细胞淋巴瘤患者参加临床试验的障碍。
Leuk Lymphoma. 2015;56(9):2747-9. doi: 10.3109/10428194.2015.1010079. Epub 2015 Feb 17.
9
How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.如何使用 frailtypack 验证来自随机对照试验荟萃分析的个体患者数据的失效时间替代终点。
PLoS One. 2020 Jan 28;15(1):e0228098. doi: 10.1371/journal.pone.0228098. eCollection 2020.
10
Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.复发/难治性弥漫性大B细胞淋巴瘤的临床疗效与安全性：一项系统文献综述
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-355.e6. doi: 10.1016/j.clml.2014.02.012. Epub 2014 Mar 1.
引用本文的文献
1
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.国际协作在多发性骨髓瘤试验中进行和报告微小残留病灶评估。
Leukemia. 2021 Jan;35(1):18-30. doi: 10.1038/s41375-020-01012-4. Epub 2020 Aug 11.
2
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.使用肿瘤标志物连续动态分析进行个体化预后预测。
Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.
3
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).一线弥漫性大 B 细胞淋巴瘤中无进展生存期作为总生存期替代终点的个体患者水平分析（SEAL）。
J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.
4
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.随机临床试验入组的弥漫性大 B 细胞淋巴瘤（DLBCL）患者的 24 个月无进展生存（PFS24）和后续结果。
Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.
5
Balancing patient value and payer cost in hematologic malignancies: can it be done?在血液系统恶性肿瘤中平衡患者价值与支付方成本：这能做到吗？
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13.
本文引用的文献
1
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.一线滤泡性淋巴瘤治疗中 30 个月完全缓解作为替代终点：多个随机试验的个体患者水平分析。
J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.
2
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?弥漫性大B细胞淋巴瘤：R-CHOP方案治疗失败后该怎么办？
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):366-378. doi: 10.1182/asheducation-2016.1.366.
3
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.初治失败的弥漫性大B细胞淋巴瘤：超高危特征及实验性疗法的基准研究
Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.
4
2016 US lymphoid malignancy statistics by World Health Organization subtypes.2016年按世界卫生组织亚型分类的美国淋巴系统恶性肿瘤统计数据。
CA Cancer J Clin. 2016 Nov 12;66(6):443-459. doi: 10.3322/caac.21357. Epub 2016 Sep 12.
5
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.美国非霍奇金淋巴瘤亚型分布、地理人口统计学模式和生存情况：1998 年至 2011 年国家癌症数据库的纵向分析。
Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086. Epub 2015 Jul 27.
6
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.利妥昔单抗用于一线缓解期侵袭性B细胞淋巴瘤患者的维持治疗：随机NHL13试验结果
Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.
7
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.现代随机试验中以无进展生存期对比总生存期作为转移性结直肠癌一线终点的个体患者数据分析：来自消化系统癌症数据库分析与研究的结果
J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10.
8
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.在初治弥漫性大B细胞淋巴瘤患者中使用或不使用贝伐单抗的R-CHOP方案：MAIN研究最终结果
Haematologica. 2014 Aug;99(8):1343-9. doi: 10.3324/haematol.2013.100818. Epub 2014 Jun 3.
9
Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.比较基于 pixantrone 的方案（CPOP-R）与基于多柔比星的治疗（CHOP-R）治疗弥漫性大 B 细胞淋巴瘤。
Ann Oncol. 2013 Oct;24(10):2618-2623. doi: 10.1093/annonc/mdt289. Epub 2013 Aug 14.
10
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
Zotero 插件